Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus Plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin α-1 As an Adjuvant

Overview

Journal Appl Environ Microbiol

Specialties Environmental Health
Microbiology

Date 2015 Mar 31

PMID 25819954

Citations 21

Authors

Yi-Gang Xu

Xue-Ting Guan

Zhong-Mei Liu

Chang-Yong Tian

Li-Chun Cui

Affiliations

Soon will be listed here.

Abstract

Classical swine fever, caused by classical swine fever virus (CSFV), is a highly contagious disease that results in enormous economic losses in pig industries. The E2 protein is one of the main structural proteins of CSFV and is capable of inducing CSFV-neutralizing antibodies and cytotoxic T lymphocyte (CTL) activities in vivo. Thymosin α-1 (Tα1), an immune-modifier peptide, plays a very important role in the cellular immune response. In this study, genetically engineered Lactobacillus plantarum bacteria expressing CSFV E2 protein alone (L. plantarum/pYG-E2) and in combination with Tα1 (L. plantarum/pYG-E2-Tα1) were developed, and the immunogenicity of each as an oral vaccine to induce protective immunity against CSFV in pigs was evaluated. The results showed that recombinant L. plantarum/pYG-E2 and L. plantarum/pYG-E2-Tα1 were both able to effectively induce protective immune responses in pigs against CSFV infection by eliciting immunoglobulin A (IgA)-based mucosal, immunoglobulin G (IgG)-based humoral, and CTL-based cellular immune responses via oral vaccination. Significant differences (P < 0.05) in the levels of immune responses were observed between L. plantarum/pYG-E2-Tα1 and L. plantarum/pYG-E2, suggesting a better immunogenicity of L. plantarum/pYG-E2-Tα1 as a result of the Tα1 molecular adjuvant that can enhance immune responsiveness and augment specific lymphocyte functions. Our data suggest that the recombinant Lactobacillus microecological agent expressing CSFV E2 protein combined with Tα1 as an adjuvant provides a promising strategy for vaccine development against CSFV.

Citing Articles

Metabolic engineering of Lactobacilli spp. for disease treatment.

Yang Y, Yu P, Huang Y, Zhang W, Nie Y, Gao C Microb Cell Fact. 2025; 24(1):53.

PMID: 40050843 PMC: 11887175. DOI: 10.1186/s12934-025-02682-4.

The Immunomodulatory Effects and Applications of Probiotic Lactiplantibacillus plantarum in Vaccine Development.

He G, Long H, He J, Zhu C Probiotics Antimicrob Proteins. 2024; 16(6):2229-2250.

PMID: 39101975 DOI: 10.1007/s12602-024-10338-9.

Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.

Ou B, Yang Y, Lv H, Lin X, Zhang M BioDrugs. 2023; 37(2):143-180.

PMID: 36607488 PMC: 9821375. DOI: 10.1007/s40259-022-00575-1.

Oral vaccination with recombinant expressing Aha1 against infections in common carps.

Zhao Z, Wang H, Zhang D, Guan Y, Siddiqui S, Feng-Shan X Virulence. 2022; 13(1):794-807.

PMID: 35499101 PMC: 9067532. DOI: 10.1080/21505594.2022.2063484.

The Development of Classical Swine Fever Marker Vaccines in Recent Years.

Li F, Li B, Niu X, Chen W, Li Y, Wu K Vaccines (Basel). 2022; 10(4).

PMID: 35455351 PMC: 9026404. DOI: 10.3390/vaccines10040603.

References

Alander M, Satokari R, Korpela R, Saxelin M, Mattila-Sandholm T, von Wright A . Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol. 1999; 65(1):351-4. PMC: 91031. DOI: 10.1128/AEM.65.1.351-354.1999. View

Chen H . Recent advances in mucosal vaccine development. J Control Release. 2000; 67(2-3):117-28. DOI: 10.1016/s0168-3659(00)00199-1. View

Rau H, Revets H, Balmelli C, McCullough K, Summerfield A . Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo. Vet Res. 2005; 37(1):155-68. DOI: 10.1051/vetres:2005049. View

Voigt H, Merant C, Wienhold D, Braun A, Hutet E, Le Potier M . Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2). Vaccine. 2007; 25(31):5915-26. DOI: 10.1016/j.vaccine.2007.05.035. View

Xu Y, Li Y . Induction of immune responses in mice after intragastric administration of Lactobacillus casei producing porcine parvovirus VP2 protein. Appl Environ Microbiol. 2007; 73(21):7041-7. PMC: 2074969. DOI: 10.1128/AEM.00436-07. View

Hou X, Yu L, Liu J, Wang G . Surface-displayed porcine epidemic diarrhea viral (PEDV) antigens on lactic acid bacteria. Vaccine. 2007; 26(1):24-31. PMC: 7115547. DOI: 10.1016/j.vaccine.2007.10.065. View

Brandhonneur N, Loizel C, Chevanne F, Wakeley P, Jestin A, Le Potier M . Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres. Int J Pharm. 2009; 373(1-2):16-23. DOI: 10.1016/j.ijpharm.2009.01.020. View

Qiao X, Li G, Wang X, Li X, Liu M, Li Y . Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice. BMC Microbiol. 2009; 9:249. PMC: 2797526. DOI: 10.1186/1471-2180-9-249. View

Tarradas J, Argilaguet J, Rosell R, Nofrarias M, Crisci E, Cordoba L . Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs. Vet Microbiol. 2009; 142(1-2):51-8. DOI: 10.1016/j.vetmic.2009.09.043. View

10.

Wei C, Liu J, Hou X, Yu L, Lee J, Kim C . Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99. Vaccine. 2009; 28(24):4113-8. DOI: 10.1016/j.vaccine.2009.05.088. View

11.

Toledo J, Barrera M, Farnos O, Gomez S, Rodriguez M, Aguero F . Human αIFN co-formulated with milk derived E2-CSFV protein induce early full protection in vaccinated pigs. Vaccine. 2010; 28(50):7907-14. DOI: 10.1016/j.vaccine.2010.09.073. View

12.

Jiang Y, Ma Z, Zhao P, Pan Y, Liu Y, Feng J . Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B. J Int Med Res. 2011; 38(6):2053-62. DOI: 10.1177/147323001003800620. View

13.

Villena J, Salva S, Aguero G, Alvarez S . Immunomodulatory and protective effect of probiotic Lactobacillus casei against Candida albicans infection in malnourished mice. Microbiol Immunol. 2011; 55(6):434-45. DOI: 10.1111/j.1348-0421.2011.00334.x. View

14.

Xu Y, Cui L, Tian C, Zhang G, Huo G, Tang L . Immunogenicity of recombinant classic swine fever virus CD8(+) T lymphocyte epitope and porcine parvovirus VP2 antigen coexpressed by Lactobacillus casei in swine via oral vaccination. Clin Vaccine Immunol. 2011; 18(11):1979-86. PMC: 3209017. DOI: 10.1128/CVI.05204-11. View

15.

Zhao L, Liu M, Ge J, Qiao X, Li Y, Liu D . Expression of infectious pancreatic necrosis virus (IPNV) VP2-VP3 fusion protein in Lactobacillus casei and immunogenicity in rainbow trouts. Vaccine. 2012; 30(10):1823-9. DOI: 10.1016/j.vaccine.2011.12.132. View

16.

Medina E, Guzman C . Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine. 2001; 19(13-14):1573-80. DOI: 10.1016/s0264-410x(00)00354-6. View

17.

Perdigon G, Fuller R, Raya R . Lactic acid bacteria and their effect on the immune system. Curr Issues Intest Microbiol. 2001; 2(1):27-42. View

18.

Belyakov I, Hel Z, Kelsall B, Kuznetsov V, Ahlers J, Nacsa J . Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 2001; 7(12):1320-6. DOI: 10.1038/nm1201-1320. View

19.

Li C, Zhang T, Saibara T, Nemoto Y, Ono M, Akisawa N . Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. Int Immunopharmacol. 2002; 2(1):39-46. DOI: 10.1016/s1567-5769(01)00136-9. View

20.

Armengol E, Wiesmuller K, Wienhold D, Buttner M, Pfaff E, Jung G . Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus. J Gen Virol. 2002; 83(Pt 3):551-560. DOI: 10.1099/0022-1317-83-3-551. View